ALLERGY Net: High omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis
High dose, 7-day to 1-h omalizumab pretreatment controls recurrent venom immunotherapy reactions in mastocytosis.
Chief Allergology Department
Euroclinic Hospital, Athens
8 Fidippidou st.
Hellas (Greece) Tel: ++302107774666/ ++306932421516 Fax: ++302106010842 E-mail: email@example.com
No abstract is available for this article.